Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants
← catalyst calendarNCT07726914 · readout in 40 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
58estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-06 | estimated | When the study began enrolling |
| Primary completion | 2026-09-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Graft Versus Host Disease
Interventions
- Drug: Belumosudil — also filed as SAR445761, REZUROCK
- Drug: Belumosudil — also filed as SAR445761, REZUROCK
Primary outcomes
what the primary-completion date above is the date OFAUClast
measured Baseline (H0) to Day 3 (H48) for each of the 2 periods
Cmax
measured Baseline (H0) to Day 3 (H48) for each of the 2 periods
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed